Skip to main content
Addgene

pcDNA3-ALK2 K235R
(Plasmid #80872)

Full plasmid sequence is not available for this item.

Loading...

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 80872 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pcDNA3
  • Vector type
    Mammalian Expression

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    ALK2
  • Alt name
    ACVR1
  • Alt name
    activin A receptor type 1
  • Species
    H. sapiens (human)
  • Mutation
    K235R
  • Entrez Gene
    ACVR1 (a.k.a. ACTRI, ACVR1A, ACVRLK2, ALK2, FOP, SKR1, TSRI)
  • Promoter CMV
  • Tag / Fusion Protein
    • HA (C terminal on backbone)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site EcoRI (not destroyed)
  • 3′ cloning site XhoI (not destroyed)
  • 5′ sequencing primer CMV-F
  • 3′ sequencing primer BGH-rev
  • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pcDNA3-ALK2 K235R was a gift from Aristidis Moustakas (Addgene plasmid # 80872 ; http://n2t.net/addgene:80872 ; RRID:Addgene_80872)
  • For your References section:

    The protein kinase LKB1 negatively regulates bone morphogenetic protein receptor signaling. Raja E, Tzavlaki K, Vuilleumier R, Edlund K, Kahata K, Zieba A, Moren A, Watanabe Y, Voytyuk I, Botling J, Soderberg O, Micke P, Pyrowolakis G, Heldin CH, Moustakas A. Oncotarget. 2016 Jan 12;7(2):1120-43. doi: 10.18632/oncotarget.6683. 10.18632/oncotarget.6683 PubMed 26701726